Professional Overview
Craig Wirth is an accomplished finance executive with extensive experience in the pharmaceutical and biotechnology industries. As the Associate Director of Finance for Medical Affairs and Pharmacovigilance at Eisai US, he leverages his expertise in financial planning, analysis, and strategic decision-making to drive organizational success.
Experience Summary
Current Role
In his current role at Eisai US, Craig is responsible for overseeing the financial operations of the company's medical affairs and pharmacovigilance departments. He plays a key role in aligning financial strategies with business objectives, optimizing resource allocation, and providing valuable insights to support informed decision-making. Through his leadership, Craig has played a pivotal role in enhancing financial efficiency and contributing to the overall growth and profitability of Eisai's medical affairs and pharmacovigilance functions.
Career Progression
Prior to his current position, Craig held various finance-related roles at leading pharmaceutical and biotechnology companies, including PDS Biotechnology Corporation, Molecular Templates, Edge Therapeutics, Inc., LEO Pharma Inc. US, Daiichi Sankyo, Merck/Schering-Plough, and Schering-Plough. Throughout his career, he has consistently demonstrated a track record of driving operational improvements, implementing effective financial strategies, and contributing to the successful execution of business initiatives.
Academic Background
Craig holds a Bachelor's degree in Accounting from Rutgers University, where he honed his financial acumen and analytical skills.
Areas of Expertise
- Financial planning and analysis
- Budgeting and forecasting
- Cost management and optimization
- Business performance reporting
- Strategic decision-making
- Cross-functional collaboration
- Process improvement and streamlining
Professional Impact
- Played a pivotal role in enhancing the financial efficiency and strategic alignment of Eisai's medical affairs and pharmacovigilance functions
- Successfully implemented innovative financial strategies that contributed to the growth and profitability of the organizations he has served
- Demonstrated a proven track record of driving operational improvements and contributing to the successful execution of business initiatives
Conclusion
With his extensive experience, financial expertise, and strategic mindset, Craig Wirth is well-positioned to continue driving meaningful impact in the pharmaceutical and biotechnology industries. His commitment to continuous improvement and his ability to collaborate cross-functionally make him a valuable asset to organizations seeking to optimize their financial operations and support their overall business objectives.
